Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator
SCIE
SCOPUS
- Title
- Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator
- Authors
- Ahn, GO; Botting, KJ; Patterson, AV; Ware, DC; Tercel, M; Wilson, WR
- Date Issued
- 2006-06-14
- Publisher
- Elsevier
- Abstract
- Metabolic reduction can be used to activate prodrugs in hypoxic regions of tumours, but reduction by ionising radiation is also theoretically attractive. Previously, we showed that a cobalt(III) complex containing 8-hydroxyquinoline (8-HQ) and cyclen ligands releases 8-HQ efficiently on irradiation in hypoxic solutions [Ahn G-O, Ware DC, Denny WA, Wilson WR. optimization of the auxiliary ligand shell of cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat Res 2004;162:315-25]. Here we investigate an analogous Co(III) complex containing the potent DNA minor groove alkylator azachloromethylbenzindoline (azaCBI, (1) under bar) to determine whether it releases (1) under bar on radiolytic and/or enzymatic reduction under hypoxia. Monitoring by HPLC, the azaCBI ligand in the Co(III)(cyclen)(azaCBI) complex M slowly hydrolysed in aqueous solution, in contrast to the free ligand 1 which readily converted to its reactive cyclopropyl form. Irradiation of 2 (3050 mu M) in hypoxic solutions released (1) under bar with yields of 0.57 mu mol/J in formate buffer and 0.13 mu mol/J in human plasma. Using bioassay methods, cytotoxic activation by irradiation of at 1 mu M in hypoxic plasma was readily detectable at clinically relevant doses (>= 1 Gy), with a estimated yield of (1) under bar of 0.075 mu mol/J. Release of 1 from 2 was also observed in hypoxic HT29 cultures without radiation, with subsequent conversion of 1 to its O-glucuronide. Surprisingly, overexpression of human cytochrome P450 reductase in A549 cells did not increase the rate of metabolic reduction of 2, suggesting that other reductases and/or non-enzymatic reductants are responsible. Thus the cobalt(III) complex 2 is a promising prodrug capable of being activated to release a very potent cytotoxin when reduced by either ionising radiation or cells under hypoxic conditions. (c) 2006 Elsevier Inc. All rights reserved.
- Keywords
- tumour hypoxia; prodrug; ionising radiation; Co(III) complex; CBI; DNA minor groove alkylator; MULTICELLULAR LAYER CULTURES; PREDICTS RADIATION RESPONSE; EXPLOITING TUMOR HYPOXIA; SELECTIVE CYTOTOXINS; IN-VITRO; EXTRAVASCULAR TRANSPORT; CANCER-CHEMOTHERAPY; NITROGEN MUSTARDS; BIOREDUCTIVE DRUG; ELECTRON-TRANSFER
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/16882
- DOI
- 10.1016/J.BCP.2006.03.007
- ISSN
- 0006-2952
- Article Type
- Article
- Citation
- BIOCHEMICAL PHARMACOLOGY, vol. 71, no. 12, page. 1683 - 1694, 2006-06-14
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.